Moderna : A good FY 2023 publication – 2024 guidance confirmed
>2023 results exceeded expectations - Moderna yesterday reported its Q4 2023 results, with sales coming in at $ 2.8bn (vs $ 2.5bn expected), bearing in mind that full-year sales ($ 6.8bn) had already been published. As expected, Spikevax sales fell sharply (-43%), mainly due to the decline in volumes over the period. On the operating front, EBIT came to $ 6m (vs -$ 480m expected), benefiting from lower COGS (-52%; -$ 990m), partly offset by higher R&D (+16%; +$ 195m...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.